Abstract:Progressive kidney fibrosis precedes end-stage renal failure in up to a third of patients with diabetes mellitus. Elevated intra-renal transforming growth factor-β (TGF-β) is thought to underlie disease progression by promoting deposition of extracellular matrix and epithelialmesenchymal transition. GW788388 is a new TGF-β type I receptor inhibitor with a much improved pharmacokinetic profile compared with SB431542. We studied its effect in vitro and found that it inhibited both the TGF-β type I and type II receptor kinase activities, but not that of the related bone morphogenic protein type II receptor. Further, it blocked TGF-β-induced Smad activation and target gene expression, while decreasing epithelialmesenchymal transitions and fibrogenesis. Using db/db mice, which develop diabetic nephropathy, we found that GW788388 given orally for 5 weeks significantly reduced renal fibrosis and decreased the mRNA levels of key mediators of extracellular matrix deposition in kidneys. Our study shows that GW788388 is a potent and selective inhibitor of TGF-β signalling in vitro and renal fibrosis in vivo. Abbreviations ActRII, activin type II Receptor; ALK, activin receptor-like kinase; caALK, constitutively active ALK; β-gal, β-galactosidase; BMP, bone morphogenic protein; BMPRII, BMP type II receptor; BRE, BMP responsive element; COL, collagen; CTGF, connective tissue growth factor; ECM, extracellular matrix; EMT, epithelial to mesenchymal transition; FN, fibronectin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GW788388, 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl) pyridin-2-yl)-N-(tetrahydro-2Hpyran4-yl) benzamide; MMP, matrix metalloproteinase; NMuMG, namru murine mammary gland; PAI-1, plasminogen activator inhibitor 1; PAS, picric acid stain; PSmad, phosphorylated Smad; RCC4, renal cell carcinoma; RT-PCR, reverse transcriptase polymerase chain reaction; SB431542, 4-(5-benzo(1,3) dioxol5-yl-4-pyridin-2-yl-1H -imidazol-2-yl)-benzamide; Smad, small phenotype and mothers against DPP related protein; α-SMA, α-smooth muscle actin; TGF-β, transforming growth factor-β; TβRII, TGF-β type II receptor; TIMP, Tissue inhibitor of metalloproteinase; VHL, von Hippel Lindau.

Disparate Phospho-Smad2 Levels in Advanced Type 2 Diabetes Patients with Diabetic Nephropathy and Early Experimental Db/db Mouse Model.

Smad2 Phosphorylation in Diabetic Kidney Tubule Epithelial Cells is Associated with Modulation of Several Transforming Growth Factor-β Family Members.

Smad3 Promotes AKI Sensitivity in Diabetic Mice Via Interaction with P53 and Induction of NOX4-dependent ROS Production

FSP1-specific SMAD2 knockout in renal tubular, endothelial, and interstitial cells reduces fibrosis and epithelial-to-mesenchymal transition in murine STZ-induced diabetic nephropathy

The Renal TGF-β System in the db/db Mouse Model of Diabetic Nephropathy

The Protective Role of Smad7 in Diabetic Kidney Disease: Mechanism and Therapeutic Potential

Latent TGF-β1 Protects Against Diabetic Kidney Disease Via Arkadia/Smad7 Signaling

TGF-β signaling in diabetic nephropathy: An update

Podocyte and endothelial-specific elimination of BAMBI identifies differential transforming growth factor-β pathways contributing to diabetic glomerulopathy

Disruption of Smad7 Promotes ANG II-Mediated Renal Inflammation and Fibrosis Via Sp1-TGF-β/Smad3-NF.κB-Dependent Mechanisms in Mice

Β-Cell Smad2 Null Mice Have Improved Β-Cell Function and Are Protected from Diet-Induced Hyperglycemia

The Function of Smad 2 Protein in Diabetic Nephropathy and Its Clinical Application

Smad3 deficiency promotes beta cell proliferation and function in db/db mice via restoring Pax6 expression

A novel role of snail in regulating tuberin/AMPK pathways to promote renal fibrosis in the new mouse model of type II diabetes

Low TGFβ1 expression prevents and high expression exacerbates diabetic nephropathy in mice

Regulatory mechanism of TGF-β1/SGK1 pathway in tubulointerstitial fibrosis of diabetic nephropathy

TFPI2 suppresses the interaction of TGF-β2 pathway regulators to promote endothelial-mesenchymal transition in diabetic nephropathy

Smad3 Deficiency Protects Mice from Obesity-Induced Podocyte Injury That Precedes Insulin Resistance

Oral administration of GW788388, a kinase inhibitor of the TGF-β type I and type II receptors, reduces renal fibrosis in db/db mice

LRNA9884, a Novel Smad3-Dependent Long Noncoding RNA, Promotes Diabetic Kidney Injury in Db/db Mice Via Enhancing MCP-1-Dependent Renal Inflammation.

AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice